World’s First Solid-Tumor CAR-T Product Advances in Clinical Use: First International Patient Completes Cell Collection at Jiahui International Cancer Center
July 6, 2026, Shanghai - July 6, 2026, Shanghai - Jiahui International Cancer Center (JICC) announced today that a 59-year-old male patient from New Zealand has successfully completed T cell collection of satricabtagene autoleucel injection (CT041) at the center. This marks the world’s first solid tumor CAR-T product approved for marketing and welcomes the first foreign patient to complete T cell collection in China. This milestone not only confirms China's global competitiveness in the clinical translation and application of cell therapy, but also conveys to the world the confidence and confidence of China's innovative therapies in serving patients around the world.
Patients and the medical team of Jiahui Cancer Center
According to reports, the patient was previously diagnosed with gastroduodenal adenocarcinoma. The standard treatment in New Zealand was not effective, the tumor continued to progress, and there was no better treatment option. After searching online, the patient learned that the world's first new CAR-T drug for solid tumors will soon be approved for marketing in China (approved for marketing on June 22, 2026), and Shanghai Jiahui International Hospital is one of the first institutions to apply this therapy. In view of the fact that the hospital has accumulated rich experience in the field of CAR-T treatment as a comprehensive international hospital and has provided treatment to cancer patients from Singapore, the United States, New Zealand, Russia and other countries, the patient immediately contacted the hospital.
At the suggestion of the Jiahui International Cancer Center team, the patient underwent pre-detection of Claudin18.2 and HER2 target expression in New Zealand. The results are encouraging - its Claudin18.2 expression level reaches 95%, which is highly consistent with the indications of satricabtagene autoleucel injection. Taking advantage of the 30-day visa-free policy window for New Zealand citizens to enter China, the patient immediately decided to go to Shanghai for treatment.
Dr. Linli Xuan, Director of the Department of Medical Oncology at Jiahui International Cancer Center, said: "We are honored to be one of the first institutions to use this world's first solid tumor CAR-T treatment program. Unlike the treatment of hematological tumors and solid tumors, which are often scattered in different departments, Jiahui International Cancer The Center is committed to building a one-stop cancer diagnosis and treatment platform. At present, the center has integrated the advantages and resources of the entire hospital and has established a standardized process system covering detection and evaluation, cell collection, reinfusion management, and adverse reaction monitoring. The center has accumulated a wealth of successful cases and is good at customizing personalized CAR-T diagnosis and treatment plans for each patient. "
Apheresis is the first step in the entire CAR-T treatment process. After the cell preparation is completed, the patient will receive reinfusion and continue subsequent treatment under the full management of the multidisciplinary team of Jiahui Cancer Center.
Note: CT041 (satricabtagene autoleucel injection) has been approved for marketing by the China National Medical Products Administration. The information described in this article is based on public information and hospital disclosures. Specific treatment plans need to be evaluated by professional doctors based on the patient's condition.
About Jiahui International Cancer Center
Jiahui International Cancer Center is affiliated to Shanghai Jiahui International Hospital and is led by Linli Xuan and other clinical experts in cancer diagnosis and treatment. It is committed to providing patients around the world with full-cycle cancer diagnosis and treatment solutions that meet international standards. Since its establishment, the center has established a strategic cooperation with the Massachusetts General Hospital Cancer Center, a teaching hospital affiliated with Harvard Medical School in the United States. Relying on a multidisciplinary diagnosis and treatment model, it gathers domestic and foreign expert resources, combines cutting-edge technology and innovative drugs, and develops personalized treatment plans for patients of all cancer types. The center has provided full-cycle cancer diagnosis and treatment services from tumor risk assessment, tumor screening, precise molecular diagnosis, to tumor surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, interventional therapy, etc. It has outstanding advantages in the fields of autologous stem cell transplantation and CAR-T cell therapy, and has provided international medical services to cancer patients from many countries and regions around the world. As the first authorized international hospital in Shanghai and one of the first batch of high-level social medical insurance pilot institutions, Shanghai Jiahui International Hospital is one of the few comprehensive international hospitals in Shanghai that has its own pathology department, independent blood bank, and ICU. Its 35 sub-professional departments provide one-stop solutions and strong professional support for the diagnosis and treatment of cancer center patients. The hospital's diversified payment system covers various payment modes such as medical insurance, commercial insurance direct payment, commercial insurance self-pay and then claims, critical illness insurance, and "Shanghai Huibao", providing patients with more payment options.
About Shanghai Jiahui International Hospital
Shanghai Jiahui International Hospital is located at No. 689 Guiping Road, Xuhui District. It is the first authorized international hospital in Shanghai and the first to become one of the first high-level private medical insurance pilot institutions in Shanghai. The hospital was put into operation in October 2017 with an approved bed capacity of 500. Currently, it has opened more than 35 departments, including clinical centers of excellence such as Jiahui International Cancer Center, Women's and Children's Medical Center, Orthopedics and Sports Health Management Center, and Heart Center, as well as key disciplines such as general practice, surgery, and 7*24-hour emergency department. Most of the medical team comes from top tertiary hospitals in China and well-known overseas medical institutions, and is committed to jointly creating an efficient, safe, integrated, and humanized medical service model. As a pioneer in Shanghai's international medical service system, Jiahui International Hospital has been selected as a designated hospital for medical security at the China International Import Expo for many years in a row, and has won many honors such as the "Excellent Service and Effective Security" award and the "Most Beautiful Service Window". At the same time, after being reviewed by the Joint Commission International (JCI), Shanghai Jiahui International Hospital, Jiahui Health (Shanghai Jing'an) and Jiahui Health (Shanghai Yangpu) all passed JCI certification, the international gold standard for medical quality, with nearly full scores, and were awarded official gold seal certificates.